Certican 0,25 mg / 0, 75 mg Tablet.
PDF Leaflet Revision Date: 27 February 2023
Clinical Summary
Quick overview from the medicine insert
Indication
To reduce the risk of organ rejection in kidney, heart, and liver transplant patients.
Dosage (summary)
Kidney/heart: 0.75 mg twice daily; Liver: 1 mg twice daily.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy and breastfeeding.
Key Drug Interactions
- CYP3A4 inhibitors
- CYP3A4 inducers
- Ciclosporin
Contraindications
- Hypersensitivity to everolimus
- Pregnancy
- Lactation
- Live vaccines
Common side effects
- Infections
- Hyperlipidaemia
- Diabetes mellitus
- Headache
- Hypertension
Counselling Points
- Monitor for infections and blood glucose levels.
- Avoid live vaccines.
- Use effective contraception during treatment.
Serious warnings
- Increased risk of infections
- Lymphomas
- Renal dysfunction with ciclosporin
- Interstitial lung disease
Important Disclaimer
The Certican 0,25 mg / 0, 75 mg Tablet. professional information leaflet below is the property of Novartis South Africa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
